newsfilter
← Latest News
PR Newswire·

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia

Phase 2a clinical trial in Friedreich's ataxia has been initiated and is currently recruiting patients BOSTON, March 28, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, d